Actusnews Wire - French company specializing in the dissemination of regulated information

  DMS GROUP company press release from 20/04/2023

  20/04/2023 - 18:15

Record quarterly revenue: EUR 10.1 million in the 1st quarter of 2023, organic growth +16% - Confirmation of 2023 targets and perspectives

Record quarterly revenue: €10.1 million in the 1st quarter of 2023, organic growth +16%

  • Radiology: 6% growth in 1st quarter / +22% in the United States / First deliveries of record order from Fujifilm Healthcare Italy will begin 2nd quarter

  • Bone densitometry: strong quarterly growth: +69%

Confirmation of 2023 targets and perspectives

  • €40 million in revenue, i.e., double-digit organic growth

  • Expected increase in EBITDA margin


Diagnostic Medical Systems Group (Euronext Growth Paris - FR0012202497 - ALDMS) French medical imaging specialist, announces its consolidated revenue for the 1st quarter of 2023 (period from January 1 to March 31, 2023). Following the divestment of 17.00% of Hybrigenics' capital in February 2023[1], the DMS Group currently retains a 24.77% stake in the capital. As of January 1, 2023 Hybrigenics is no longer consolidated in the DMS Group accounts.

Unaudited consolidated data in M€
IFRS standards
1st quarter 2023 1st quarter 2022 Variation
Revenue 10.1 8.7[2] +16%
Radiology activity 7.7 7.3 +6%
Bone densitometry activity 2.4 1.4 +69%


The DMS Group generated consolidated revenue of €10.1 million in the 1st quarter 2023 representing +16% of organic growth2 and marking the largest quarterly revenue ever earned in a 1st quarter.


Review by activity

In Radiology, revenue amounted to €7.7 million, a quarterly growth of +6%. 1st quarter activity did not include any deliveries of the 96 FDX Visionary-RF Premium remote-controlled radiology tables won in a tender by Fujifilm Healthcare Italy[3]. The first deliveries for this order will begin in the 2nd quarter of 2023 and will ramp up throughout the year.

The Radiology business continued its strong development in the United States at the start of the exercise, with +22% growth in the region, driven by distribution agreements with Fujifilm Healthcare and Carestream Health. The DMS Group manufactures white-label remote-controlled radiology tables offered by:

  • Fujifilm Healthcare in Europe, Africa, Middle East, and North America.
  • Canon Medical Systems Europe in the Europe area.
  • Carestream Health in North and South America.

DMS Group also markets its solutions under its own brand, Apelem, to a network of 140 distributors around the world.

In Bone densitometry, the Group registered a strong 1st quarter 2023, recording +69% growth. This performance reflects the success of our distribution agreement with Fujifilm Healthcare as well as an acceleration in sales in Europe and Asia, where sales activities had begun to resume at the end of 2022.


Confirmation of 2023 revenue target: €40 million

At the end of an historic 1st quarter, the Group remains confident in its objective of €40 million consolidated annual revenue. The Radiology activity will begin deliveries of the 96 tables to Fujifilm Healthcare Italy over the next few quarters, and sustained activity in both radiology and bone densitometry will allow the Group to reach double-digit organic growth compared to 2022.

The Group also confirms the improvement in its profitability in 2023, with an expected improvement in its EBITDA margin[4].

As set forth in the Imaging 2027 plan, the DMS Group has fixed the objectives of registering €60 million revenue and an EBITDA margin of 14% in 2027.


Financial calendar 2023

Date Event
April 28, 2023 Publication of 2022 annual results
July 20, 2023 Publication of 2023 half-year revenue
September 29, 2023 Publication of 2023 half-year results
October 19, 2023 Publication of 2023 3rd quarter revenue
January 18, 2024 Publication of 2023 annual revenue
April 30, 2024 Publication of 2023 annual results

The publications will be made after Euronext Paris market closing. These dates are given as an indication, they may be changed if necessary.


About DMS Group
The DMS Group is a French specialist and recognized player in medical imaging, with high-end imaging solutions dedicated to digital radiology and bone densitometry, through its DMS Imaging division.
The DMS Group is on every continent through a network of over 140 national distributors, subsidiaries and joint ventures.
DMS Group is quoted on the Paris Euronext market (ISIN: FR0012202497 - memo: ALDMS).

More information on



DMS Group    
Samuel SANCERNI Chairman & CEO +33(0)4 67 50 49 00
Mathieu OMNES Investors relations +33(0)1 53 67 36 92
Fatou-Kiné N'DIAYE Press Relations +33(0)1 53 67 36 34

[1]Read press release of February 8, 2023.

[2]Revenue for the 1st quarter of 2023 does not include revenue from Hybrigenics, which has been deconsolidated since January 1, 2023. As a reminder, Hybrigenics had generated revenue of €0.2 million in the 1st quarter 2022.

[3]Read press release of January 12, 2023

[4]EBITDA corresponds to the recurring operating income before interest, taxes, depreciations, and amortization.

This publication embed "🔒 Actusnews SECURITY MASTER".
- SECURITY MASTER Key: yGlyk8lsk23Flm5wZsZqaGKVmGxiyGeZZ2aVnGdtaMedmW6RmZxoapyVZnBqmWtp
- Check this key:

  Original Source: DMS GROUP